5-aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 24, Issue 4, 1997, Pages 287-288

  Odes, H Selwyn ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; TABLETS;

EID: 0030757211     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199706000-00026     Document Type: Article

References (11)

1. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383-9.
2. Giaffer MH, Holdsworth CD, Lennard-Jones JE. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 1992;6:479-85.
3. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1982;317:1625-9.
4. Brogden RN, Sorkin EM. Mesalazine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989;38:500-23.
5. Goldstein F. Immunosuppressant therapy of inflammatory bowel disease: pharmacological and clinical aspects. J Clin Gastroenterol 1987;6:654-8.
6. Present DH, Meltzer SJ, Krumholz PM, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
7. Oren R, Arber N, Odes HS, et al. Methotrexate in chronic ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
8. Kashyap PK, Targan SR, Plevy SE, et al. Cyclosporin in the treatment of refractory ulcerative colitis: clinical determinants of a successful outcome at 6 months. Gastroenterology 1994;106:A756.
9. Azad Kahn AK, Howes DT, Piris J, et al. Optimum dose of sulphasalazine for maintenance treatment of ulcerative colitis. Gut 1980;21:232-40.
10. Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995;20:203.
11. Hanauer SB. Medical therapy in ulcerative colitis. In: Kirsner JB, Shorter GR, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins, 1995:664-94.